Our top pick for
Beginners

Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.
Gamida Cell Ltd is a biotechnology business based in the US. Gamida Cell shares (GMDA) are listed on the NASDAQ and all prices are listed in US Dollars. Gamida Cell employs 79 staff and has a market cap (total outstanding shares value) of USD$566.5 million.
Our top pick for
Beginners
Our top pick for
Building a portfolio
Our top pick for
Advanced traders
52-week range | USD$2.7296 - USD$12.47 |
---|---|
50-day moving average | USD$9.5594 |
200-day moving average | USD$6.766 |
Wall St. target price | USD$19.5 |
PE ratio | N/A |
Dividend yield | N/A (0%) |
Earnings per share (TTM) | USD$-3.203 |
*Signup bonus information updated weekly.
The value of any investment can go up or down depending on news, trends and market conditions. We are not investment advisers, so do your own due diligence to understand the risks before you invest.
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Gross profit TTM | USD$0 |
---|---|
Return on assets TTM | -38.27% |
Return on equity TTM | -100.68% |
Profit margin | 0% |
Book value | $1.222 |
Market capitalisation | USD$566.5 million |
TTM: trailing 12 months
There are currently 724,804 Gamida Cell shares held short by investors – that's known as Gamida Cell's "short interest". This figure is 32.2% up from 548,463 last month.
There are a few different ways that this level of interest in shorting Gamida Cell shares can be evaluated.
Gamida Cell's "short interest ratio" (SIR) is the quantity of Gamida Cell shares currently shorted divided by the average quantity of Gamida Cell shares traded daily (recently around 724804). Gamida Cell's SIR currently stands at 1. In other words for every 100,000 Gamida Cell shares traded daily on the market, roughly 1000 shares are currently held short.
However Gamida Cell's short interest can also be evaluated against the total number of Gamida Cell shares, or, against the total number of tradable Gamida Cell shares (the shares that aren't held by "insiders" or major long-term shareholders – also known as the "float"). In this case Gamida Cell's short interest could be expressed as 0.01% of the outstanding shares (for every 100,000 Gamida Cell shares in existence, roughly 10 shares are currently held short) or 0.0199% of the tradable shares (for every 100,000 tradable Gamida Cell shares, roughly 20 shares are currently held short).
Such a low SIR usually points to an optimistic outlook for the share price, with fewer people currently willing to bet against Gamida Cell.
Find out more about how you can short Gamida Cell stock.
We're not expecting Gamida Cell to pay a dividend over the next 12 months.
Over the last 12 months, Gamida Cell's shares have ranged in value from as little as $2.7296 up to $12.47. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Gamida Cell's is 2.0241. This would suggest that Gamida Cell's shares are significantly more volatile than the average for this exchange and represent a higher risk.
Gamida Cell Ltd., a clinical-stage biopharmaceutical company, develops cell therapies to cure blood cancers and serious blood diseases. The company's lead product candidate is omidubicel, a nicotinamide expanded hematopoietic stem cells and differentiated immune cells, including T cells that is in Phase 3 studies in patients with high-risk hematologic malignancies, as well as in Phase 1/2 clinical trial in patients with severe aplastic anemia. It is also developing GDA-201, a natural killer cell-based cancer immunotherapy, which is in Phase 1/2 studies for the treatment of relapsed or refractory non-Hodgkin lymphoma and multiple myeloma. The company was founded in 1998 and is headquartered in Jerusalem, Israel.
Everything we know about the Toast Inc IPO, plus information on how to buy in.
Everything we know about the Cyxtera IPO, plus information on how to buy in.
Everything we know about the ATI Physical Therapy IPO, plus information on how to buy in.
Everything we know about the Sportradar IPO, plus information on how to buy in.
Everything we know about the Longboard Pharmaceuticals Inc IPO, plus information on how to buy in.
Everything we know about the Prometheus Biosciences Inc IPO, plus information on how to buy in.
Everything we know about the Olo Inc IPO, plus information on how to buy in.
Everything we know about the China Eco-Materials Group Co Limited IPO, plus information on how to buy in.
Everything we know about the Gain Therapeutics Inc IPO, plus information on how to buy in.
Everything we know about the Karat Packaging Inc IPO, plus information on how to buy in.